eyeg News

Breaking news: Two-thirds of this week's IPOs broke issue. Last week, we noted that the recent stretch of strong first-day pops (+26%) with weak follow-through performance (-3%) was likely unsustainable. This week, IPOs averaged a loss of...read more

EyeGate Pharmaceuticals, a late-stage biotech developing a treatment for eye inflammation, raised $10 million by offering 1.2 million shares and warrants at $8.50. EyeGate postponed a $25 million NASDAQ IPO in late 2014 before listing on the OTCQB in February. In mid-July, the company had set terms to raise $13 million when its stock traded at $15 on the OTCQB, and on July 30...read more

The largest biotech ever to go public is on the calendar for this week, targeting a $2.2 billion valuation at IPO. Ten IPOs and two blank check companies plan to raise over $2 billion. Half are set to have a market cap of less than $200 million, and for these our ...read more

EyeGate Pharmaceuticals, a late-stage biotech developing a treatment for eye inflammation, announced terms for its initial public offering of shares on the NASDAQ on Wednesday. The Waltham, MA-based company plans to raise as much as $13 million by offering 0.87 million shares based on its July 14 share price of $15. At that price, EyeGate Pharmaceuticals would command a fully...read more